



LATEST NEWS BUSH IN SAUDI TO COURT ALLY ON MIDEAST PEACE



### Were you there?

Share the news you capture with Reuters and the world.

[Submit your photos](#)



Reuters/C-SPAN/  
Find out what Am  
[Buy now >](#)

You are here: [Home](#) > [Business & Finance](#) > Article

HOME

BUSINESS & FINANCE

Markets

Deals

Industries

Stocks

Stock Buzz

Funds

ETFs

Currencies

Commodities

Options

Bonds

Analyst Research

Portfolio

NEWS

[Do More With Reuters](#)

[RSS](#)

[Mobile](#)

[Podcasts](#)

[Newsletters](#)

[You Witness News](#)

**Partner Services**

[CareerBuilder](#)

[Affiliate Network](#)

**Professional Products**

[Support \(Customer Zone\)](#)

[Reuters Media](#)

[Financial Products](#)

[Find a financial adviser](#)

**About Reuters**

## Where Are The Medical Journal Articles About Problems With Studies On Zetia And Vytorin?

powered by BlogBurst

POSTED: Friday, January 11, 2008

FROM BLOG: [Drug Injury Watch](#) - Prescription Drug Side Effects News and Information from Attorney Tom Lamb

The following blog post is from an independent writer and is not connected with Reuters News. The opinions and views expressed herein are those of the author and are not endorsed by Reuters.com.

### Dr. Blumsohn Shines His Bright Light On This Troubling Situation And Provides A Lengthy List Of Recent Blog Posts About Zetia And Vytorin

(Posted by Tom Lamb at [DrugInjuryWatch.com](#))

Over at the [Scientific Misconduct Blog](#), Dr. Aubrey Blumsohn has posted an article, "Ezetimibe - where are our medical journals?", which makes one wonder if Zetia and Vytorin are getting off easy in the medical journal world.

From Dr. Blumsohn's January 11, 2008 post on Zetia (ezetimibe):

The huge ethical and scientific problems with the drug Ezetimibe have been discussed widely in the lay press (especially in the New York Times). The problems have been discussed by patients, on the internet and in the blogosphere. However as of today, a search of our key medical journals reveals no hint of any ethical discussion. No discussion of the principles of good science. Not even a worthy news report. Nothing at all.

- The British medical Journal : No discussion
- The Lancet: On 24 November 2007 in the midst of the saga, the Lancet published a review entitled "The safety of statins in clinical practice" Jane Armitage, Vol. 370, Issue 9601 Pages 1781-1790. There was no relevant discussion or associated editorial in that issue or in any subsequent issue.
- NEJM: No discussion
- JAMA: No discussion

Dr. Blumsohn then contrasts this "silence" in the medical journals to the discussion of these problems with Zetia and Vytorin during the last few months in articles by bloggers who write regularly about medical and pharmaceutical topics. His list of 35 blog posts includes our earlier article, "[Cholesterol Drug Zetia May Cause Serious Liver Injury Including Hepatitis And Liver Failure](#)".

And to Dr. Blumsohn's list of recent blog articles about this troubling situation we can add "[Behind The Curtain: That Secret Vytorin Panel](#)", which was posted by Ed Silverman at his [Pharmalot](#) blog on January 11.

We close with this observation by Dr. Blumsohn:

One wonders how long our key medical journals will retain any credibility as honest impartial portals for discussion of science and the principles of good medicine.

Of course, we will continue to watch for developments concerning Zetia and Vytorin.

[Read more from this blogger at Drug Injury Watch](#) | [Let us know what you think of this feature](#)

**Reuters.com:** [Help and Contact Us](#) | [Advertise With Us](#) | [Mobile](#) | [Newsletters](#) | [RSS](#)  | [Interactive TV](#) | [Labs](#) | [Reuters in Se](#)  
**Reuters Corporate:** [Copyright](#) | [Disclaimer](#) | [Privacy](#) | [Professional Products](#) | [Professional Products Support](#) | [About Reuters](#) |

**International Editions:** [Africa](#) | [Arabic](#) | [Argentina](#) | [Brazil](#) | [Canada](#) | [Chinese Simplified](#) | [Chinese Traditional](#) | [France](#) | [Gerr](#)  
[Russia](#) | [Spain](#) | [United Kingdom](#) | [United States](#)

Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Reuters journalists are subject to the disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please